Citigroup
SABS icon

Citigroup’s SAB Biotherapeutics SABS Stock Holding History

Citigroup’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Buy
36,805
+6,831
+23% +$27.2K ﹤0.01% 4153
2025
Q4 		$112K Buy
29,974
+29,142
+3,503% +$95.9K ﹤0.01% 4270
2025
Q3 		$1.67K Buy
+832
New +$1.88K ﹤0.01% 5524
2022
Q4 		– Sell
-49
Closed – – 5932
2022
Q3 		$0 Sell
49
-15
-23% -$149 ﹤0.01% 6259
2022
Q2 		$1K Sell
64
-638
-91% -$13.4K ﹤0.01% 6083
2022
Q1 		$26K Buy
702
+573
+444% +$26.5K ﹤0.01% 5028
2021
Q4 		$10K Buy
+129
New +$12.1K ﹤0.01% 5563

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's SABS Position: Q1 2026 in Review

Citigroup increased its SAB Biotherapeutics (SABS) stake by 23% in Q1 2026, buying an estimated $27.2K and bringing the position to 36,805 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Citigroup first reported a position in SABS in Q4 2021 and has held it in 7 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Citigroup held 36,805 shares of SAB Biotherapeutics worth $141K as of Q1 2026.
  • Citigroup bought 6,831 SAB Biotherapeutics shares in Q1 2026, an estimated $27.2K.
  • SAB Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4153 holding.
  • Citigroup first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 7 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.